He A - Search Results

1

Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis.

Yu W, Zhang Z, Min D, Yang Q, Du X, Tang L, Lin F, Sun Y, Zhao H, Zheng S, He A, Li H, Yao Y, Shen Z. Yu W, et al. Among authors: he a. Eur J Cancer. 2014 Apr;50(6):1125-36. doi: 10.1016/j.ejca.2014.01.030. Epub 2014 Feb 21. Eur J Cancer. 2014. PMID: 24565852

2

Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute.

Qi WX, He AN, Tang LN, Shen Z, Yao Y. Qi WX, et al. Med Oncol. 2012 Sep;29(3):2229-33. doi: 10.1007/s12032-011-0021-y. Epub 2011 Jul 7. Med Oncol. 2012. PMID: 21748427 Clinical Trial.

3

The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.

Qi WX, Tang LN, He AN, Shen Z, Yao Y. Qi WX, et al. Lung. 2011 Dec;189(6):437-43. doi: 10.1007/s00408-011-9332-1. Epub 2011 Oct 11. Lung. 2011. PMID: 21986852

4

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Qi WX, Tang LN, He AN, Shen Z, Yao Y. Qi WX, et al. J Cancer Res Clin Oncol. 2012 May;138(5):745-51. doi: 10.1007/s00432-012-1155-9. Epub 2012 Jan 19. J Cancer Res Clin Oncol. 2012. PMID: 22258853 Review.

5

Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.

Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Qi WX, et al. Curr Med Res Opin. 2012 Apr;28(4):643-50. doi: 10.1185/03007995.2012.675880. Epub 2012 Mar 29. Curr Med Res Opin. 2012. PMID: 22414178 Review.

6

Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.

Qi WX, He AN, Tang LN, Shen Z, Lin F, Yao Y. Qi WX, et al. Jpn J Clin Oncol. 2012 May;42(5):427-31. doi: 10.1093/jjco/hys030. Epub 2012 Mar 26. Jpn J Clin Oncol. 2012. PMID: 22450929

7

Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.

He A, Qi W, Huang Y, Sun Y, Shen Z, Zhao H, Yang Y, Yao Y. He A, et al. Int J Clin Oncol. 2013 Jun;18(3):498-505. doi: 10.1007/s10147-012-0409-5. Epub 2012 Apr 26. Int J Clin Oncol. 2013. PMID: 22534798

8

Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Qi WX, et al. Lung. 2012 Oct;190(5):477-85. doi: 10.1007/s00408-012-9399-3. Epub 2012 Jun 19. Lung. 2012. PMID: 22711060 Review.

9

Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.

Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y. Qi WX, et al. Br J Clin Pharmacol. 2013 Apr;75(4):919-30. doi: 10.1111/j.1365-2125.2012.04417.x. Br J Clin Pharmacol. 2013. PMID: 22882307 Free PMC article. Review.

10

Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials.

Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y. Qi WX, et al. Int J Cancer. 2013 Jan 15;132(2):E66-73. doi: 10.1002/ijc.27775. Epub 2012 Sep 1. Int J Cancer. 2013. PMID: 22890856 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,717 results

Search Page

Filters